Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. Vomiting should be induced mechanically, or with syrup of ipecac, if the patient is alert adequate pharyngeal and laryngeal reflexes. The first dose should be accompanied by an appropriate cathartic. If repeated doses are used, the cathartic might be included with alternate doses as required.

Hypotension is usually hypovolemic and should respond to fluids. Vasopressors and other supportive measures should be employed as indicated. Moderate Agents which induce the hepatic isoenzymes CYP2E1 and CYP1A2, such as rifampin, may potentially increase the risk for acetaminophen-induced hepatotoxicity via generation of a greater percentage of acetaminophen's hepatotoxic metabolites.

Rifamycins, inducers of CYP3A4, may cause increased clearance of hydrocodone, which could result in lack of efficacy or the development of an abstinence syndrome in a patient who had developed physical dependence to hydrocodone.

A higher hydrocodone dose may be needed if used with rifamycins. Major Monitor for respiratory depression and sedation if hydrocodone and itraconazole are coadministered; consider dosage adjustments if necessary. Concomitant administration of a CYP3A4 inhibitor, such as itraconazole, may cause an increase in hydrocodone plasma concentrations, which could increase or prolong adverse effects.

Minor Use caution when administering ivacaftor and hydrocodone concurrently. Co-administration of ivacaftor with CYP3A substrates, such as hydrocodone, can theoretically increase hydrocodone exposure leading to increased or prolonged therapeutic effects and adverse events; however, the clinical impact of this has not yet been determined. Major Monitor for respiratory depression and sedation if hydrocodone and ketoconazole are coadministered; consider dosage adjustments if necessary.

Concomitant administration of a CYP3A4 inhibitor, such as ketoconazole, may cause an increase in hydrocodone plasma concentrations, which could increase or prolong adverse effects. Moderate Concurrent use of antidiarrheals and opiate agonists, can lead to severe constipation and possibly additive CNS depression.

Minor Concurrent use of hydrocodone with strong laxatives that rapidly increase gastrointestinal motility, such as lactulose, may decrease hydrocodone absorption. Major Acetaminophen can be hepatotoxic, and lamotrigine appears to be a potential cause of progressive and fatal hepatotoxicity despite drug discontinuation. A 35 year-old developed fulminant liver failure possibly caused by lamotrigine. She was taking several other drugs including acetaminophen.

Minor The manufacturer recommends that oral compounds known to interact with antacids, such as acetaminophen, should not be taken within 2 hours of dosing with lanthanum carbonate. Major Monitor for respiratory depression and sedation if hydrocodone and lapatinib are coadministered; consider dosage adjustments if necessary. Concomitant administration of a CYP3A4 inhibitor, such as lapatinib, may cause an increase in hydrocodone plasma concentrations, which could increase or prolong adverse effects.

Moderate Concomitant use of hydrocodone with letermovir may increase hydrocodone plasma concentrations and prolong opioid adverse reactions, including hypotension, respiratory depression, profound sedation, coma, and death. The magnitude of this interaction may be increased in patients also receiving cyclosporine. Moderate Lincosamides, which have been shown to exhibit neuromuscular blocking action, can enhance the effects of opiate agonists if used concomitantly, enhancing respiratory depressant effects.

They should be used together with caution and the patient carefully monitored. Moderate Monitor for excessive hypotension and sedation during coadministration of lofexidine and hydrocodone. Lofexidine can potentiate the effects of CNS depressants. The effect of concomitant administration of lomitapide with other hepatotoxic medications is unknown. More frequent monitoring of liver-related tests may be warranted.

Concurrent use of selected antidiarrheals e. Moderate Loxapine can potentiate the actions of other CNS depressants such as opiate agonists. Caution should be exercised with simultaneous use of these agents due to potential excessive CNS effects. Moderate Concomitant use of hydrocodone and lumacaftor; ivacaftor may decrease the systemic exposure of hydrocodone, leading to decreased analgesia and, potentially, development of an abstinence syndrome in physically dependent patients.

If used together, evaluate the patient at frequent intervals and consider hydrocodone dosage adjustments until stable drug effects are achieved. If lumacaftor; ivacaftor is subsequently discontinued, the hydrocodone plasma concentrations will increase, which may increase or prolong therapeutic and adverse effects, and may cause life-threatening respiratory depression.

Monitor patients closely and reduce the hydrocodone dosage as appropriate. Hydrocodone is a substrate of CYP3A4. Lumacaftor is a strong CYP3A inducer. Moderate Due to the CNS effects of lurasidone, caution should be used when lurasidone is given in combination with other centrally acting medications such as opiate agonists. Minor Concurrent use of hydrocodone with strong laxatives that rapidly increase gastrointestinal motility, such as magnesium citrate, may decrease hydrocodone absorption.

Minor Because of the CNS-depressant effects of magnesium sulfate, additive central-depressant effects can occur following concurrent administration with CNS depressants such as opiate agonists.

Caution should be exercised when using these agents concurrently. Minor Concurrent use of hydrocodone with strong laxatives that rapidly increase gastrointestinal motility, such as magnesium sulfate; potassium sulfate; sodium sulfate, may decrease hydrocodone absorption.

Drugs that may cause additive CNS effects include maprotiline. Moderate Concomitant use of hydrocodone with meprobamate may lead to hypotension, profound sedation, coma, respiratory depression and death.

Drugs that may cause additive CNS effects include anxiolytics, sedatives, and hypnotics. Limit the use of opiate pain medications with skeletal muscle relaxants to only patients for whom alternative treatment options are inadequate.

If acetaminophen; hydrocodone or hydrocodone; ibuprofen are initiated in a patient taking a skeletal muscle relaxant, reduced initial doses are recommended. Avoid prescribing opiate cough medications in patients taking skeletal muscle relaxants. Moderate Opiate agonists antagonize GI motility and can decrease the gastroprokinetic effects of metoclopramide. Major Coadministration of metyrapone and acetaminophen may result in acetaminophen toxicity.

Acetaminophen glucuronidation is inhibited by metyrapone. It may be advisable for patients to avoid acetaminophen while taking metyrapone. Other drugs that may also cause drowsiness, such as opiate agonists, should be used with caution. Moderate The concomitant administration of metyrosine with opiate agonists can result in additive sedative effects. Major Monitor for respiratory depression and sedation if hydrocodone and mifepristone, RU are coadministered; consider dosage adjustments if necessary.

Concomitant administration of a CYP3A4 inhibitor, such as mifepristone, may cause an increase in hydrocodone plasma concentrations, which could increase or prolong adverse effects. Moderate Concurrent use of hydrocodone with strong laxatives that rapidly increase gastrointestinal motility, such as mineral oil, may decrease hydrocodone absorption.

Minor Injectable minocycline contains magnesium sulfate heptahydrate. Because of the CNS-depressant effects of magnesium sulfate, additive central-depressant effects can occur following concurrent administration with CNS depressants such as opiate agonists. The effect of concomitant administration of mipomersen with other hepatotoxic medications is unknown.

Theoretically, coadministration of hydrocodone and a CYP2D6 inhibitor, such as mirabegron, may result in a reduction in the analgesic effect of hydrocodone. This interaction has not been proven.

Drugs that may cause additive CNS effects include mirtazapine. Major Use caution if mitotane and hydrocodone are used concomitantly, and monitor for decreased efficacy of hydrocodone and a possible change in dosage requirements. Mitotane, a strong inducer of CYP3A4, may cause increased clearance of hydrocodone, which could result in lack of efficacy or the development of an abstinence syndrome in a patient who had developed physical dependence to hydrocodone.

A higher hydrocodone dose may be needed if used with mitotane. Additionally, mitotane can cause sedation, lethargy, vertigo, and other CNS adverse reactions; additive CNS effects may occur initially when mitotane is given concurrently with hydrocodone. Minor Use caution if mitotane and acetaminophen are used concomitantly, and monitor for decreased efficacy of acetaminophen. Modafinil, an inducer of CYP3A4, may cause increased clearance of hydrocodone, which could result in lack of efficacy or the development of an abstinence syndrome in a patient who had developed physical dependence to hydrocodone.

A higher hydrocodone dose may be needed if used with modafinil. Moderate Concomitant use of opiate agonists with other central nervous system CNS depressants, such as molindone, can potentiate the effects of the opiate and may lead to additive CNS or respiratory depression, profound sedation, or coma. Major Concomitant use of hydrocodone with morphine may lead to hypotension, profound sedation, coma, respiratory depression and death. Prior to concurrent use, assess the level of tolerance to CNS depression that has developed and the patient's overall response to treatment.

Also, consider a using a lower dose of morphine. Moderate Concomitant use of opiate agonists with other central nervous system CNS depressants, such as nabilone, can potentiate the effects of the opiate and may lead to additive CNS or respiratory depression, profound sedation, or coma.

Nafcillin, an inducer of CYP3A4, may cause increased clearance of hydrocodone, which could result in lack of efficacy or the development of an abstinence syndrome in a patient who had developed physical dependence to hydrocodone.

A higher hydrocodone dose may be needed if used with nafcillin. Major Avoid the concomitant use of nalbuphine and opiate agonists, such as hydrocodone. Nalbuphine may cause withdrawal symptoms in patients receiving chronic opiate agonists.

Concurrent use of nalbuphine with other opiate agonists can cause additive CNS, respiratory, and hypotensive effects. Major Monitor for respiratory depression and sedation if hydrocodone and nefazodone are coadministered; consider dosage adjustments if necessary. Concomitant administration of a CYP3A4 inhibitor, such as nefazodone, may cause an increase in hydrocodone plasma concentrations, which could increase or prolong adverse effects.

Major Monitor for respiratory depression and sedation if hydrocodone and nelfinavir are coadministered; consider dosage adjustments if necessary. Concomitant administration of a CYP3A4 inhibitor, such as nelfinavir, may cause an increase in hydrocodone plasma concentrations, which could increase or prolong adverse effects. Major The potential for hypotension may be increased when coadministering nesiritide with opiate agonists.

Moderate Netupitant is a moderate inhibitor of CYP3A4 and should be used with caution in patients receiving concomitant medications that are primarily metabolized through CYP3A4, such as hydrocodone.

The plasma concentrations of hydrocodone can increase when coadministered with netupitant; the inhibitory effect on CYP3A4 can last for multiple days. Nevirapine, an inducer of CYP3A4, may cause increased clearance of hydrocodone, which could result in lack of efficacy or the development of an abstinence syndrome in a patient who had developed physical dependence to hydrocodone. A higher hydrocodone dose may be needed if used with nevirapine.

Major Monitor for respiratory depression, sedation and decreased analgesic effect if hydrocodone and nicardipine are coadministered; consider dosage adjustments if necessary. Concomitant administration of a CYP3A4 inhibitor, such as nicardipine, may cause an increase in hydrocodone plasma concentrations, which could increase or prolong adverse effects.

Theoretically, coadministration of hydrocodone and a CYP2D6 inhibitor, such as nicardipine, may result in a reduction in the analgesic effect of hydrocodone. Minor Nitroglycerin can cause hypotension. This action may be additive with other agents that can cause hypotension such as opiate agonists. Patients should be monitored more closely for hypotension if nitroglycerin is used concurrently with opiate agonists. Moderate Octreotide can cause additive constipation with opiate agonists such as hydrocodone.

Monitor patients during concomitant use. Plasma concentrations and efficacy of hydrocodone may be reduced if these drugs are administered concurrently, which could also result in an abstinence syndrome in a patient who had developed physical dependence to hydrocodone. A higher hydrocodone dose may be needed if used with oritavancin.

Oxcarbazepine, an inducer of CYP3A4, may cause increased clearance of hydrocodone, which could result in lack of efficacy or the development of an abstinence syndrome in a patient who had developed physical dependence to hydrocodone.

A higher hydrocodone dose may be needed if used with oxcarbazepine. Moderate Monitor frequently for an increase in hydrocodone-related adverse reactions e. Consider dosage reduction of hydrocodone until stable drug effects are achieved if concurrent use is necessary.

If palbociclib is discontinued, consider an increased dose of hydrocodone and monitor for signs of opioid withdrawal. Moderate Concomitant use of drugs that can cause CNS depression, such as hydrocodone and paliperidone, can increase both the frequency and the intensity of adverse effects such as drowsiness, sedation, and dizziness.

Moderate Papaverine is a benzylisoquinoline alkaloid of opium and may have synergistic effects with opiate agonists. Concurrent use of papaverine with potent CNS depressants could lead to enhanced sedation. Theoretically, coadministration of hydrocodone and a CYP2D6 inhibitor, such as paroxetine, may result in a reduction in the analgesic effect of hydrocodone.

Coadministration of pazopanib and hydrocodone, a CYP3A4 substrate, may cause an increase in systemic concentrations of hydrocodone. Use caution when administering hydrocodone and pazopanib together.

Theoretically, coadministration of hydrocodone and a CYP2D6 inhibitor, such as peginterferon alfa-2b, may result in a reduction in the analgesic effect of hydrocodone.

Moderate In clinical trials, patients taking opiate agonists often required higher serum pegvisomant concentrations to achieve appropriate IGF-I suppression compared with patients not receiving opiate agonists. The mechanism of this interaction is unknown. The combination of perampanel particularly at high doses with ethanol has led to decreased mental alertness and ability to perform complex tasks such as driving , as well as increased levels of anger, confusion, and depression; similar reactions should be expected with concomitant use of other CNS depressants, such as opiate agonists.

Drugs that may cause additive CNS effects include pimozide. Moderate Concomitant administration of antipyretics, such as acetaminophen, may decrease an individual's immunological response to the pneumococcal vaccine. A post-marketing study conducted in Poland using a non-US vaccination schedule 2, 3, 4, and 12 months of age evaluated the impact of prophylactic oral acetaminophen on antibody responses to Prevnar Data show that acetaminophen, given at the time of vaccination and then dosed at 6 to 8 hour intervals for 3 doses on a scheduled basis, reduced the antibody response to some serotypes after the third dose of Prevnar 13 when compared to the antibody responses of infants who only received antipyretics 'as needed' for treatment.

However, reduced antibody responses were not observed after the fourth dose of Prevnar 13 with prophylactic acetaminophen. Minor Concurrent use of hydrocodone with strong laxatives that rapidly increase gastrointestinal motility, such as polyethylene glycol, may decrease hydrocodone absorption.

Polyethylene Glycol; Electrolytes; Ascorbic Acid: Polyethylene Glycol; Electrolytes; Bisacodyl: Major Monitor for respiratory depression and sedation if hydrocodone and posaconazole are coadministered; consider dosage adjustments if necessary. Concomitant administration of a CYP3A4 inhibitor, such as posaconazole, may cause an increase in hydrocodone plasma concentrations, which could increase or prolong adverse effects.

Moderate Posaconazole and acetaminophen should be coadministered with caution due to an increased potential for acetaminophen-related adverse events. Posaconazole is a potent inhibitor of CYP3A4, an isoenzyme partially responsible for the metabolism of acetaminophen. These drugs used in combination may result in elevated acetaminophen plasma concentrations, causing an increased risk for acetaminophen-related adverse events. Drugs that may cause additive CNS effects include pramipexole.

Major Pramlintide slows gastric emptying and the rate of nutrient delivery to the small intestine. Medications with the potential to slow GI motility, such as opiate agonists, should be used with caution, if at all, with pramlintide until more data are available from the manufacturer.

Minor Because pramlintide has the potential to delay the absorption of concomitantly administered medications, medications should be administered at least 1 hour before or 2 hours after pramlintide injection when the rapid onset of a concomitantly administered oral medication is a critical determinant of effectiveness i.

Moderate Consider the use of a parenteral anti-platelet agent for patients with acute coronary syndrome who require concomitant opioid agonists. Coadministration of opioid agonists with prasugrel delays and reduces the absorption of prasugrel's active metabolite due to slowed gastric emptying. Moderate Concomitant use of opiate agonists with other central nervous system CNS depressants can potentiate the effects of the opiate and may lead to additive CNS or respiratory depression, profound sedation, or coma.

Examples of drugs associated with CNS depression include pregabalin. Minor Prilocaine and acetaminophen each individually can cause methemoglobinemia. Patients treated with prilocaine who are receiving acetaminophen concurrently are at greater risk for developing methemoglobinemia.

Theoretically, coadministration of hydrocodone and a CYP2D6 inhibitor, such as propafenone, may result in a reduction in the analgesic effect of hydrocodone.

Drugs that may cause additive CNS effects include quetiapine. Major Monitor for respiratory depression, sedation and decreased analgesic effect if hydrocodone and quinine are coadministered; consider dosage adjustments if necessary. Quinine is both an inhibitor and an inducer of CYP3A4. Coadministration may cause an increase or decrease in hydrocodone plasma concentrations, which could increase or prolong adverse effects or decrease analgesic effects. Theoretically, coadministration of hydrocodone and a CYP2D6 inhibitor, such as quinine, may result in a reduction in the analgesic effect of hydrocodone.

Theoretically, coadministration of hydrocodone and a CYP2D6 inhibitor, such as ranolazine, may result in a reduction in the analgesic effect of hydrocodone. Moderate Opiate agonists e. Moderate Use caution if coadministration of ribociclib with hydrocodone is necessary, as the systemic exposure of hydrocodone may be increased resulting in an increase in treatment-related adverse reactions including sedation and respiratory depression; adjust the dose of hydrocodone if necessary.

Moderate As a cytochrome P isoenzyme inducers, rifabutin could induce the metabolism of acetaminophen. An increase in acetaminophen-induced hepatotoxicity may be seen by increasing the metabolism of acetaminophen to its toxic metabolite, NAPQI. Drugs that may cause additive CNS effects include risperidone. Major Use caution if hydrocodone and rolapitant are used concurrently, and monitor for a decrease in the efficacy of hydrocodone.

The inhibitory effect of rolapitant is expected to persist beyond 28 days for an unknown duration. Exposure to another CYP2D6 substrate, following a single dose of rolapitant increased about 3-fold on Days 8 and Day Moderate Concomitant use of opiate agonists with other central nervous system CNS depressants such as ropinirole can potentiate the effects of the opiate and may lead to additive CNS or respiratory depression, profound sedation, or coma.

Moderate Consider a reduced dose of hydrocodone with frequent monitoring for respiratory depression and sedation if concurrent use of rucaparib is necessary. If rucaparib is discontinued, consider increasing the hydrocodone dose until stable drug effects are achieved and monitor for evidence of opioid withdrawal.

Coadministration can increase hydrocodone exposure resulting in increased or prolonged opioid effects including fatal respiratory depression, particularly when an inhibitor is added to a stable dose of hydrocodone. If rucaparib is discontinued, hydrocodone plasma concentrations will decrease resulting in reduced efficacy of the opioid and potential withdrawal syndrome in a patient who has developed physical dependence to hydrocodone. Major Monitor for respiratory depression and sedation if hydrocodone and saquinavir are coadministered; consider dosage adjustments if necessary.

Concomitant administration of a CYP3A4 inhibitor, such as saquinavir, may cause an increase in hydrocodone plasma concentrations, which could increase or prolong adverse effects.

Minor Concurrent use of hydrocodone with strong laxatives that rapidly increase gastrointestinal motility, such as senna, may decrease hydrocodone absorption. Major The risk of serotonin syndrome and reduced efficacy of hydrocodone is possible if sertraline and hydrocodone are used together. Use of opioid medications with drugs known to affect the neurotransmitter system, such as sertraline, has resulted in serotonin syndrome.

Also, impairment of CYP2D6 metabolism by sertraline may reduce the conversion of hydrocodone to its active forms, thus reducing analgesic efficacy. Do not take more than milligrams of acetaminophen per day. Call your doctor if you took more than the recommended dose.

Such tasks should be avoided while taking this product. Alcohol and other CNS depressants may produce an additive CNS depression, when taken with this combination product, and should be avoided.

Hydrocodone may be habit-forming. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed. Physicians should instruct patients and caregivers to read the patient information leaflet, which appears as the last section of the labeling. Drug Interactions Patients receiving narcotics, antihistamines, antipsychotics, antianxiety agents, or other CNS depressants including alcohol concomitantly with hydrocodone bitartrate and acetaminophen oral solution may exhibit an additive CNS depression.

When combined therapy is contemplated, the dose of one or both agents should be reduced. The use of MAO inhibitors or tricyclic antidepressants with hydrocodone preparations may increase the effect of either the antidepressant or hydrocodone.

Carcinogenesis, Mutagenesis, Impairment of Fertility No adequate studies have been conducted in animals to determine whether hydrocodone has a potential for carcinogenesis, mutagenesis, or impairment of fertility. Hydrocodone has not demonstrated mutagenic potential using the Ames Salmonella-Microsomal Activation test, the Basc test on Drosophila germ cells, and the Micronucleus test on mouse bone marrow. No adequate studies have been conducted in animals to determine whether acetaminophen has a potential for carcinogenesis, mutagenesis, or impairment of fertility.

Acetaminophen has not demonstrated mutagenic potential using the Ames Salmonella-Microsomal Activation test, the Basc test on Drosophila germ cells, and the Micronucleus test on mouse bone marrow. Pregnancy Teratogenic Effects Pregnancy Category C There are no adequate and well controlled studies in pregnant women. Hydrocodone bitartrate and acetaminophen oral solution should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nonteratogenic Effects Babies born to mothers who have been taking opioids regularly prior to delivery will be physically dependent. The withdrawal signs include irritability and excessive crying, tremors, hyperactive reflexes, increased respiratory rate, increased stools, sneezing, yawning, vomiting, and fever. These signs usually appear during the first few days of life. The intensity of the syndrome does not always correlate with the duration of maternal opioid use or dose.

There is no consensus on the best method of managing withdrawal. Labor and Delivery Narcotic analgesics cross the placental barrier. The closer to delivery and the larger the dose used, the greater the possibility of respiratory depression in the newborn. Narcotic analgesics should be avoided during labor if delivery of a premature infant is anticipated. If the mother has received narcotic analgesics during labor, newborn infants should be observed closely for signs of respiratory depression.

The effect of hydrocodone, if any, on the later growth, development, and functional maturation of the child is unknown. Nursing Mothers Acetaminophen is excreted in breast milk in small amounts, but the significance of its effects on nursing infants is not known. It is not known whether hydrocodone is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from hydrocodone and acetaminophen, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Nursing Mothers Acetaminophen is excreted in breast milk in small amounts, but the significance of its effects on nursing infants is not known. It is not known whether hydrocodone is excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants from hydrocodone and acetaminophen, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use Safety and effectiveness in pediatric patients have not been established. Geriatric Use Clinical studies of hydrocodone bitartrate 5 mg and acetaminophen mg did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.

In severe overdosage, apnea , circulatory collapse, cardiac arrest and death may occur. Acetaminophen In acetaminophen overdosage: Renal tubular necrosis, hypoglycemic coma, and coagulation defects may also occur. Early symptoms following a potentially hepatotoxic overdose may include: Clinical and laboratory evidence of hepatic toxicity may not be apparent until 48 to 72 hours post-ingestion.

Treatment A single or multiple drug overdose with hydrocodone and acetaminophen is a potentially lethal polydrug overdose, and consultation with a regional poison control center is recommended. Immediate treatment includes support of cardiorespiratory function and measures to reduce drug absorption. Oxygen, intravenous fluids, vasopressors, and other supportive measures should be employed as indicated. Assisted or controlled ventilation should also be considered. For hydrocodone overdose, primary attention should be given to the reestablishment of adequate respiratory exchange through provision of a patent airway and the institution of assisted or controlled ventilation.

The narcotic antagonist naloxone hydrochloride is a specific antidote against respiratory depression which may result from overdosage or unusual sensitivity to narcotics, including hydrocodone.

Since the duration of action of hydrocodone may exceed that of the antagonist, the patient should be kept under continued surveillance, and repeated doses of the antagonist should be administered as needed to maintain adequate respiration. A narcotic antagonist should not be administered in the absence of clinically significant respiratory or cardiovascular depression. Gastric decontamination with activated charcoal should be administered just prior to N- acetylcysteine NAC to decrease systemic absorption if acetaminophen ingestion is known or suspected to have occurred within a few hours of presentation.

Serum acetaminophen levels should be obtained immediately if the patient presents 4 hours or more after ingestion to assess potential risk of hepatotoxicity; acetaminophen levels drawn less than 4 hours post-ingestion may be misleading.

DESCRIPTION

Minor It has been suggested by in vitro and in vivo animal studies that acarbose augments the activity of 325mg hepatic isoenzyme CYP2E1, which is responsible for metabolism of acetaminophen to its toxic reactive metabolite. The total daily dosage should not exceed 6 tablets. Ethinyl Estradiol; Norethindrone Acetate; Ferrous fumarate: Pediatric Use Safety and effectiveness in pediatric patients have not been established. Drowsi ness, mental clouding, albuterol buy bodybuildinghydrocodone bitartrate acetaminophen 10mg 325mg, impairment of acetaminophen and physical performance, hydrocodone bitartrate acetaminophen 10mg 325mg, anxiety, fear, dysphoria10mg dependence, mood changes. The 'Norco High' and Abuse Hydrocodone, the narcotic component 325mg Norco, makes it ripe for abuse, especially since it's easily acetaminophen as a generic hydrocodone is not an expensive drug. Because many drugs are excreted in human milk and because of 10mg potential for serious adverse reactions in nursing infants from hydrocodone and acetaminophen, a decision should be made whether to discontinue nursing or to discontinue the drug, taking into account the importance of the drug to the mother. If used together, extreme caution hydrocodone needed, and a reduced tramadol dose is recommended. The combination of isoniazid and acetaminophen has caused severe hepatotoxicity bitartrate at least one patient; studies in rats have demonstrated that pre-treatment with isoniazid potentiates acetaminophen hepatotoxicity. Rifamycins, inducers of CYP3A4, may bitartrate increased clearance of hydrocodone, which could result in lack of efficacy or the development of an abstinence syndrome in a patient who had developed physical dependence to hydrocodone.

FDA warns of acetaminophen liver damage

M367 (Acetaminophen and Hydrocodone 325 mg / 10 mg)

Dosing should be based on weight whenever possible. Concomitant administration of a CYP3A4 inhibitor, such as darunavir, may cause an increase in hydrocodone plasma concentrations, which could increase or prolong adverse effects. Avoid prescribing opiate cough medications in patients taking deutetrabenazine. Acetaminophen, coadministration of hydrocodone and a CYP2D6 inhibitor, such as amiodarone, may result 325mg a reduction in the analgesic effect of hydrocodone. Hypotension is usually hypovolemic and should respond to fluids. Concurrent use can decrease the clearance of trimetrexate and thus increase its plasma levels. Anxiety, hydrocodone bitartrate acetaminophen 10mg 325mg, dizziness, drowsiness, dysphoria, euphoria, fear, general malaise, impairment of mental and physical performance, lethargy, light-headedness, mental clouding, mood changes, hydrocodone dependence, sedation, somnolence progressing to stupor or coma. Minor Due to the CNS depression potential of all local anesthetics, they should be used with caution with other agents that can cause respiratory depression, such as opiate agonists. Fosaprepitant mg IV as a single dose increased the AUC of levitra buy uk given on days 1 and 4 by approximately 1. Moderate Tobacco smoking induces the cytochrome P isoenzyme CYP1A2 and may potentially increase the risk for acetaminophen-induced hepatotoxicity during overdose via enhanced generation of acetaminophen's hepatotoxic metabolite, NAPQI. The precise mechanism of action of hydrocodone and 10mg opiates is not known, although it is believed bitartrate relate to the existence of opiate receptors in the central nervous system. Patients should take the drug only for as long as it is prescribed, in the amounts prescribed, and no more frequently than prescribed. They are supplied as follows:

Norco (hydrocodone bitartrate and acetaminophen) 10mg/325 mg | Norco

Co-administration of ivacaftor with CYP3A substrates, such as hydrocodone, can theoretically increase hydrocodone exposure 10mg to increased or prolonged il costo del cialis da 5mg effects and adverse events; however, the clinical impact of this has not yet been hydrocodone. Physical dependence usually assumes clinically significant dimensions only after several weeks of continued opioid use, although a mild degree of physical dependence may develop after a few days bitartrate opioid therapy. Drospirenone; Ethinyl Estradiol; Levomefolate: Butorphanol may cause withdrawal symptoms in patients receiving chronic opiate agonists, hydrocodone bitartrate acetaminophen 10mg 325mg. To obtain the best acetaminophen outcome, 325mg should be administered as soon as bitartrate where impending or evolving liver injury is suspected. Carcinogenesis, Mutagenesis, hydrocodone bitartrate acetaminophen 10mg 325mg, Impairment of Fertility No adequate studies have hydrocodone conducted in animals to determine whether hydrocodone has a potential for carcinogenesis, mutagenesis, or impairment of fertility. Minor Theoretically, apraclonidine might potentiate the effects of CNS depressant drugs such as opiate agonists. Dermatological Skin rash, hydrocodone bitartrate acetaminophen 10mg 325mg, pruritus. Also, impairment of CYP2D6 metabolism by sertraline may reduce the conversion of hydrocodone to its active forms, thus reducing analgesic efficacy. Moderate Consider a reduced 10mg of hydrocodone with frequent monitoring for respiratory depression and sedation if concurrent use of rucaparib is necessary. Renal tubular necrosis, hydrocodone bitartrate acetaminophen 10mg 325mg, hypoglycemic coma, and thrombocytopenia may also occur. Major Monitor for respiratory depression and sedation if hydrocodone and atazanavir are coadministered; consider dosage adjustments if necessary. Moderate Bethanechol facilitates intestinal and bladder function via parasympathomimetic actions. Moderate 325mg clinical trials, patients taking opiate agonists often required higher serum pegvisomant concentrations acetaminophen achieve appropriate IGF-I suppression compared with patients not receiving opiate agonists.

Tags: buy requip 0.25mg cheapest generic cialis no prescription

© Copyright 2017 Hydrocodone bitartrate acetaminophen 10mg 325mg - Sorry, our site is unavailable in your country right now..